Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

Health officials at the Africa Centres for Disease Control and Prevention (Africa CDC) today confirmed that the current Ebola outbreak in the Democratic Republic of the Congo and Uganda is being caused by the rare Bundibugyo strain.

Bundibugyo ebolavirus was first isolated during an outbreak of hemorrhagic fever in Uganda in 2007. There are no vaccines or specific treatments approved to prevent or treat the Bundibugyo strain.

Preliminary laboratory results from the Institut National de Recherche Biomedicale (INRB) detected Ebola virus in 13 of 20 samples tested with the Bundibugyo Virus.

"Africa CDC is actively collaborating with health authorities in DRC, Uganda, and regional partners to deliver a coordinated response to confirmed Ebola Virus Disease cases linked to the Bundibugyo strain," the Africa CDC said in a statement.

"Rapid laboratory testing, contact tracing, cross-border surveillance, and enhanced infection prevention measures are already deployed to protect communities and stop the spread," it added.

Ebola Outbreak: Cases And Deaths

As of the latest update from DRC, approximately 246 suspected cases and 65 deaths have been reported, mainly in Mongwalu and Rwampara health zones.

Four deaths have been reported among laboratory-confirmed cases.

Suspected cases have also been reported in Bunia and are pending confirmation. These figures remain provisional and are being validated through laboratory confirmation, line-list harmonization, contact identification, and epidemiological investigation.

Also read: Ebola Resurfaces In Eastern DR Congo In 17th Outbreak, Claims 65 Lives: All You Need To Know

Ebola Bundibugyo Virus Kills Ugandan Man

Uganda’s Ministry of Health, in a statement, reported a confirmed Ebola Bundibugyo Virus Disease case in a 59-year-old Congolese male who was admitted to Kibuli Muslim Hospital on May 11 and died on May 14.

The country's officials reported the case as imported from DRC and have indicated that no local case has yet been confirmed.

Africa CDC noted that it remains concerned by the urban context of Bunia and Rwampara, with intense population movement, insecurity, mining-related mobility in Mongwalu, gaps in contact listing, infection prevention and control challenges, and the proximity of affected areas to Uganda and South Sudan.

What Is Bundibugyo Virus Disease?

Bundibugyo virus disease is a rare and deadly illness that has caused outbreaks in several African countries in the past.

It is also spread by contact with contaminated objects (such as clothing, bedding, needles, and medical equipment), or by contact with animals, such as bats and nonhuman primates, that are infected with BVD.

Symptoms include fever, headache, muscle pain, weakness, diarrhea, vomiting, stomach pain, and unexplained bleeding or bruising (a late stage of illness).

Read More: National Dengue Day 2026: India Reports 6,927 Cases And 10 Deaths In 2026

Ebola Outbreak: Here's How To Prevent

The US CDC advised people to avoid:

• contact with people who have symptoms such as fever, muscle pain, and rash
• contact with blood and other body fluids or objects that are contaminated with them
• visiting healthcare facilities in the affected areas for nonurgent medical care or for non-medical reasons. Avoid visiting traditional healers in the affected areas
• contact with dead bodies or items that have been in contact with dead bodies
• participating in funeral or burial practices that involve touching the body of someone who has died
• contact with bats, forest antelopes, nonhuman primates (e.g., monkeys, chimpanzees, gorillas), and blood, fluids, or raw meat from these or unknown animals.
• going into areas where bats live, such as mines or caves.

In case of infection, the CDC advises:

• Monitoring for symptoms of BVD while in the outbreak area and for 21 days after leaving.
• If you develop fever, headache, muscle pain, weakness, diarrhea, vomiting, stomach pain, and unexplained bleeding or bruising (a late stage of illness)
• Isolate immediately
• Do not travel.
• Contact local health authorities

Even as the world is still grappling with the news of a hantavirus and two separate norovirus outbreaks, the Africa Centres for Disease Control and Prevention (Africa CDC) today confirmed that the Ebola virus has resurfaced in eastern Democratic Republic of the Congo for the 17th time.

In a statement, the Africa CDC reported that there are 246 suspected cases and 65 deaths, mainly in the mining areas of Mongwalu and Rwampara, about 100 kilometers north of the provincial capital, Bunia.

While tests are being carried out to identify the strain of the virus, early indications suggest the strain is not the Zaire variant, which has been responsible for several previous outbreaks in the country, the health officials said.

The Ebola Zaire strain was prominent in Congo’s past outbreaks, including the 2018 to 2020 outbreak in the eastern region that killed more than 1,000 people.

Ebola: 17th outbreak in DR Congo

Ebola was first discovered in 1976 in the DR Congo. This is the 17th outbreak of the deadly viral disease in the country.

As per preliminary tests conducted at the Institut National de Recherche Biomédicale (INRB) in the country's capital, Kinshasa, the Ebola virus has been detected in 13 of 20 samples analysed, following consultations with DR Congo's Ministry of Health and National Public Institute.

Of the 65 deaths, four were reported among lab-confirmed cases, Africa CDC said.

Additional suspected cases have also been reported in Ituri's provincial capital, Bunia, a densely populated urban centre near the borders with Uganda and South Sudan, raising fears of regional transmission.

All affected communities and at-risk areas have been advised to follow guidelines from the national health authorities.

Also read: More Americans Exposed To Hantavirus; 41 Under Monitoring, Says CDC

What Is Ebola Virus Disease?

As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal.

People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person, such as saliva, urine, feces, or semen, or things that have body fluids of an infected person, like clothes or sheets.

How Does Transmission Work?

Read More: Another Norovirus Outbreak Confirmed Aboard Cruise Ship In France; Over 1,700 People Trapped

Ebola enters the body through cuts in the skin or when one touches their eyes, nose, or mouth. Early symptoms include fever, fatigue, and headache.

It is a highly infectious and transmissible disease; in fact, there have been cases of healthcare workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.

Cases of people conducting burial ceremonies, involving direct contact with the body of the deceased, can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk or in pregnancy-related fluids and tissues.

Symptoms include:

• feeling tired
• headache
• muscle and joint pain
• eye pain and vision problems
• weight gain
• belly pain and loss of appetite
• hair loss and skin problems
• trouble sleeping
• memory loss
• hearing loss
• depression and anxiety.

Is There Any Vaccine for Ebola?

According to the WHO, there are two vaccines against the Ebola virus. But both the Merck-developed Ervebo vaccine, administered in one dose, and Johnson & Johnson-developed Zabdeno and Mvabea vaccine, administered in a two-dose regimen, target Zaire ebolavirus.

The Ervebo vaccine is recommended for use in outbreak settings and is currently the only vaccine available in the global stockpile.

The hantavirus outbreak may no longer be confined to the luxury Dutch cruise ship MV Hondius, with health officials now assessing the possibility of wider exposure. Officials at the US Centers for Disease Control and Prevention (CDC) said that although no cases have been reported in the US so far, the agency is monitoring 41 people for possible exposure.

The 41 includes the 18 people evacuated from the hantavirus-hit ship from Spain’s Canary Islands.

Notably, of the 18 passengers evacuated, two were carried in the plane's biocontainment units out of an abundance of caution — one who tested positive and another considered a suspected case. They were quarantined at a special facility in Nebraska. The remaining 16 are being quarantined in Omaha and Atlanta.

Speaking to CNN from a biocontainment unit at the University of Nebraska Medical Center in Omaha, Dr. Stephen Kornfeld of Oregon said he “feels wonderful” and is not experiencing symptoms.

Spanish officials confirmed that after initially testing positive for hantavirus, Dr. Kornfeld has since tested negative twice for the disease, meaning no Americans currently have the illness, Forbes reported.

CDC Monitoring More People

However, an additional 16 people are being monitored by the CDC.

The new individuals were not on the cruise ship but were passengers on an April 25 flight to Johannesburg and were exposed to someone known to have been infected, said Dr. David Fitter, who is leading the CDC response to the outbreak, according to The New York Times.

Also read: Shocking Study Finds Andes Hantavirus Could Linger In Semen For Years, Pose Transmission Risk

Seven other passengers from the cruise ship had disembarked on April 24 in St. Helena, an island in the Atlantic Ocean, returned to the US on commercial flights, and are being monitored by state health departments.

As of May 14, there were no confirmed hantavirus cases in the United States, Dr. Fitter said.

“Our job is to ensure that we are monitoring and in contact with anybody that might have been on the flight this person had taken,” Dr. Fitter told reporters. The agency is “monitoring all Americans that potentially would have been exposed, whether in the US or abroad, and we have been in contact with them,” he said.

Hantavirus Outbreak: 11 Cases And 3 Deaths Reported

According to the World Health Organization (WHO), 10 people have been affected by the rat-borne virus so far, of whom three have died.

A Dutch couple is believed to have first been exposed to the virus while visiting a birdwatching site in Argentina.

The WHO has confirmed that the Andes strain of hantavirus — the only strain known to spread from person to person — is behind the outbreak.

While all passengers onboard the cruise have been taken care of by health authorities, the virus’ long incubation period remains a serious concern. This means that even asymptomatic individuals could potentially become infectious 6-8 weeks later.

WHO Guidelines On Hantavirus Exposure

The WHO recommends that people exposed to hantavirus should be:

• Monitored actively at a specified quarantine facility
• Monitored at home for 42 days from the last exposure